Annals of the Rheumatic Diseases最新文献

{"title":"Influence of canstatin on fibroblast-driven hypervascularisation in rheumatoid arthritis.","authors":"Corinna Heck, Birgit Zimmermann-Geller, Sophie Haun, Frederik Lötfering, Paula Welbrink, Daria Kürsammer, Klaus W Frommer, Mona Arnold-Gräf, Adelheid Korb-Pap, Anna Knothe, Nils Schulz, Stefan Simianer, Ingo Tarner, Walter Hermann, Christoph Biehl, Stefan Günther, Jürgen Steinmeyer, Katrin S Lips, Markus Rickert, Stefan Rehart, Ulf Müller-Ladner, Elena Neumann","doi":"10.1016/j.ard.2025.05.019","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.019","url":null,"abstract":"<p><strong>Objectives: </strong>Hypervascularisation is a dominant feature of the inflamed synovium in rheumatoid arthritis (RA). As RA synovial fibroblasts (RASFs) are key cells of synovial pathophysiology and are located adjacent to the aberrant endothelial cells (ECs), we hypothesised that this interaction might be responsible for the pathological hypervascularisation.</p><p><strong>Methods: </strong>In the severe combined immunodeficiency (SCID) mouse model for RA, RASF-mediated helix-like vessel (HLV) formation was described and modulated by canstatin, an antiangiogenic collagen IV fragment that blocks the angiopoietin (ANGPT)/Tie2 pathway in EC. ANGPT2/CD31 and CXCL2 immunofluorescence on implants and human synovium was performed. RASF were stimulated with interleukin (IL)-1β once or repetitively and immunoassays, real-time polymerase chain reaction and RNA sequencing were performed. Two-dimensional (2D) tube formation and 3-dimensional spheroid-based assays using human umbilical vein ECs and fluorescent-stained RASF with/without canstatin, IL-11 and CXCL2 were evaluated.</p><p><strong>Results: </strong>In SCID mice, RASF-specific HLV formation started early and increased until day 30. The number of HLV was significantly reduced by canstatin. Compared to osteoarthritis synovium, ANGPT2 was significantly upregulated in RA vessels. Repetitive RASF stimulation significantly decreased IL-6, IL-11 and CXCL-2 compared to RASF stimulated once with IL-1β. When RASF was stimulated once, CXCL2 and IL-11 were significantly reduced along with 2D tube formation, while repetitive stimulation significantly attenuated hypervascularisation. RNAseq revealed underlying pathways leading to altered tube formation.</p><p><strong>Conclusions: </strong>We showed that RASF affect vascularisation in vitro and in vivo. The results support the idea that canstatin is able to alter the RASF pathological HLV formation. In the SCID mouse model, this was regulated on a molecular level mediated by ANGPT2 in a vascular endothelial growth factor A-independent manner, contributing significantly to one of the central aspects of RA pathophysiology.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The TFIID complex is a new autoantibody target in systemic sclerosis.","authors":"Jean-Baptiste Vulsteke, Birthe Michiels, Vanessa Smith, Yves Piette, Marie Vanthuyne, Carole Lacout, Antoine Brochard, Mohammed Tikly, Jonas De Leeuw, Doreen Dillaerts, Tom Dehaemers, Petra De Haes, Jan L Lenaerts, Daniel Blockmans, Neil McHugh, Sarah Tansley, Emeline Vinatier, Frédéric Houssiau, Carolien Bonroy, Ellen De Langhe, Xavier Bossuyt","doi":"10.1016/j.ard.2025.05.008","DOIUrl":"10.1016/j.ard.2025.05.008","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout.","authors":"Adwoa Dansoa Tabi-Amponsah, Sarah Stewart, Lisa K Stamp, William J Taylor, Robert Terkeltaub, Nicola Dalbeth","doi":"10.1016/j.ard.2025.05.017","DOIUrl":"10.1016/j.ard.2025.05.017","url":null,"abstract":"<p><strong>Objectives: </strong>In 2016, rheumatologists and gout researchers developed a preliminary definition for gout remission. A subsequent qualitative study involving people with gout identified redundancies in the preliminary definition, prompting the development of a simplified definition consisting of no gout flares over 12 months, absence of subcutaneous tophi and serum urate <0.36 mmol/L (6 mg/dL) over 12 months. Here, we describe the evaluation and validation of the simplified definition and endorsement of this definition as the Gout, Hyperuricemia, and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout.</p><p><strong>Methods: </strong>After establishment of the simplified definition, this multiphase project involved consecutive steps: analysis of the definition across a range of gout clinical trial datasets and study populations, summary of evaluation and validation of this definition presented to G-CAN members, discussion of this definition by G-CAN members, voting and G-CAN Board endorsement.</p><p><strong>Results: </strong>The simplified definition exhibited face validity, construct validity, predictive validity, feasibility, responsiveness, and discrimination across a range of gout clinical trial datasets. It also captured both inflammatory disease activity and urate burden in gout and reflected the patient perspective on gout remission. It was suggested by G-CAN members to consider the definition as one for 'clinical gout remission' since there is no domain evaluating complete crystal dissolution. In voting, this definition was supported by 98% of G-CAN members, and the G-CAN Board endorsed the definition.</p><p><strong>Conclusions: </strong>The G-CAN definition is feasible and has high validity. We recommend that this definition is used when assessing clinical remission in gout.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence to: 'Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database'.","authors":"Yan-Li Yang, Rong-Hong Guo, James Cheng-Chung Wei, Li-Yun Zhang","doi":"10.1016/j.ard.2025.04.026","DOIUrl":"10.1016/j.ard.2025.04.026","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.","authors":"Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B M Landewé","doi":"10.1016/j.ard.2025.05.013","DOIUrl":"10.1016/j.ard.2025.05.013","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic susceptibility to membranous lupus nephritis: a genome-wide association study.","authors":"Yang Liu, Ting Gan, Yuan-Yuan Qi, Meng Tan, Lin-Lin Xu, Yang Li, Jiong Liu, Shu Qu, Lizhong Wang, Gang Chen, Ji-Cheng Lv, Zhan-Zheng Zhao, Wenjian Bi, Peipei Zhang, Ming-Hui Zhao, Ying Tan, Swapan K Nath, Hong Zhang, Xu-Jie Zhou","doi":"10.1016/j.ard.2025.05.015","DOIUrl":"10.1016/j.ard.2025.05.015","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoreactive B cells in extremes of rheumatoid arthritis disease phenotypes.","authors":"Nienke J Blomberg, Hendy Kristyanto, Marloes Verstappen, Sam Neppelenbroek, Annette H M van der Helm-van Mil, René E M Toes, Hans Ulrich Scherer","doi":"10.1016/j.ard.2025.05.006","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.006","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI).","authors":"Simon J Bowman, Raphaele Seror, Raphael Porcher, Suzanne Arends, Liseth de Wolff, Gwenny Verstappen, Valerie Devauchelle-Pensec, Sandrine Jousse-Joulin, Chiara Baldini, Michele Bombardieri, Elena Pontarini, Wolfgang Hueber, Jessica Marvel, Pushpendra Goswami, Divi Cornec, Benjamin A Fisher, Saba Nayar, Francesca Barone, Wan-Fai Ng, Jacques-Eric Gottenberg, Hendrika Bootsma, Thomas Dörner, Maggy Pincemin, Coralie Bouillot, Katherine M Hammitt, Marie Wahren-Herlenius, Joel van Roon, Gaetane Nocturne, Laurence Laigle, Philippe Moingeon, Antonia Christodoulou, Antoine G Sreih, Andre van Maurik, Wen-Hung Chen, Nicolas Wisniacki, Alena Piatrova, Roland Jonsson, Peter Gergely, Xavier Mariette","doi":"10.1016/j.ard.2025.05.004","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.004","url":null,"abstract":"<p><p>Primary Sjögren's disease (pSjD) is an autoimmune rheumatic disease involving exocrine glands and associated with high symptom burden (dryness, fatigue, pain), systemic features and salivary gland dysfunction. B-cell hyperactivity is common, with an increased risk of mucosa-associated lymphoid tissue lymphoma. This review describes the unmet need, scientific validity of outcome measures, optimisation of clinical trial design, therapeutic advances and how clinical improvement relates to health-related quality of life, additional quality-adjusted life years and economic benefit in pSjD. It derives from the EU-funded Necessity IHI Academic-Industry collaborative Consortium project while also drawing on work by the European Alliance of Associations for Rheumatology Sjögren's task force and others. The NECESSITY Consortium, formed within the framework of the Innovative Health Initiative (IHI), comprises 20 academic partners, 1 patient group partner and 4 industry partners (NECESSITY; https://necessity-h2020.eu). Patient leaders have been closely involved, with expert advice obtained from the European Medicines Agency and the United States Food and Drug Administration during the development phase of a new outcome measure, the Sjögren's Tool for Assessing Response composite response criteria. This tool is now undergoing validation through the NECESSITY IHI clinical trial and industry-sponsored trials.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatiotemporal distributions and regional disparities of rheumatoid arthritis in 953 global to local locations, 1980-2040, with deep learning-empowered forecasts and evaluation of interventional policies' benefits.","authors":"Wenyi Jin, Qian Wang, Cheng Jin, Mingyang Xue, Liming Pan, You Zeng, Yubiao Zhang, Fei Li, Claire Chenwen Zhong, Yutong Lu, Dong Wang, Yuanyuan Wan, Ningning Wu, Pengpeng Ye, Xintao Zhang, Baozhen Huang, Queran Lin","doi":"10.1016/j.ard.2025.04.009","DOIUrl":"https://doi.org/10.1016/j.ard.2025.04.009","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate global to local socioeconomic-driven distributions and inequalities in burdens of rheumatoid arthritis (RA) and to forecast long-term burdens.</p><p><strong>Methods: </strong>We analysed the prevalence, incidence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) of RA across 953 locations worldwide, as well as their inequalities and ideal frontiers. A deep-learning pipeline was developed to forecast long-term burdens with scenario simulations.</p><p><strong>Results: </strong>In 2021, RA affected 17.9 million people globally, with a 13.2% increase in incidence rate from 1990-2021, trending younger and broader. The age-standardised death rate fell 32.7% from 1980 to 2021, but global DALYs nearly doubled from 1990 to 2021. In 2021, among 652 subnational regions, West Berkshire in the UK had the highest age-standardised incidence rate (35.1; 95% uncertainty interval [UI]: 30.8-39.8). Zacatecas in Mexico had the highest age-standardised DALY rate (112.6; 95% UI: 87.2-142.7). Regions with a high sociodemographic index (SDI) bore the heaviest burden, with regional inequalities aggravating from 1990 to 2021. Over 90% of areas lagged in RA frontiers of multiple indicators. Japan uniquely showed declining trends (1990-2021), exemplified by Tokyo's age-standardised DALY rate dropping by 22.4% since 1990, unlike that in other high SDI regions. Implementing smoking control policies is forecasted to reduce RA-related deaths by 16.8% and DALYs by 20.6% among male patients in high-smoking regions like China.</p><p><strong>Conclusions: </strong>Demographic changes and uneven health infrastructure exacerbated RA burdens and disparities worldwide, with high SDI areas hardest hit while low SDI regions saw increases. Trend analysis empowered targeted policies such as localised smoking control to address these inequities.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the limit of image resolution for human expert classification of vascular ultrasound images in giant cell arteritis and healthy subjects: the GCA-US-AI project.","authors":"Claus-Juergen Bauer, Stavros Chrysidis, Christian Dejaco, Matthew J Koster, Minna J Kohler, Sara Monti, Wolfgang A Schmidt, Chetan B Mukhtyar, Pantelis Karakostas, Marcin Milchert, Cristina Ponte, Christina Duftner, Eugenio de Miguel, Alojzija Hocevar, Annamaria Iagnocco, Lene Terslev, Uffe Møller Døhn, Berit Dalsgaard Nielsen, Aaron Juche, Luca Seitz, Kresten Krarup Keller, Rositsa Karalilova, Thomas Daikeler, Sarah Louise Mackie, Karina Torralba, Kornelis S M van der Geest, Dennis Boumans, Philipp Bosch, Alessandro Tomelleri, Markus Aschwanden, Tanaz A Kermani, Andreas Diamantopoulos, Ulrich Fredberg, Nevsun Inanc, Simon M Petzinna, Shadi Albarqouni, Charlotte Behning, Valentin Sebastian Schäfer","doi":"10.1016/j.ard.2025.05.010","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.010","url":null,"abstract":"<p><strong>Objectives: </strong>Prompt diagnosis of giant cell arteritis (GCA) with ultrasound is crucial for preventing severe ocular and other complications, yet expertise in ultrasound performance is scarce. The development of an artificial intelligence (AI)-based assistant that facilitates ultrasound image classification and helps to diagnose GCA early promises to close the existing gap. In the projection of the planned AI, this study investigates the minimum image resolution required for human experts to reliably classify ultrasound images of arteries commonly affected by GCA for the presence or absence of GCA.</p><p><strong>Methods: </strong>Thirty-one international experts in GCA ultrasonography participated in a web-based exercise. They were asked to classify 10 ultrasound images for each of 5 vascular segments as GCA, normal, or not able to classify. The following segments were assessed: (1) superficial common temporal artery, (2) its frontal and (3) parietal branches (all in transverse view), (4) axillary artery in transverse view, and 5) axillary artery in longitudinal view. Identical images were shown at different resolutions, namely 32 × 32, 64 × 64, 128 × 128, 224 × 224, and 512 × 512 pixels, thereby resulting in a total of 250 images to be classified by every study participant.</p><p><strong>Results: </strong>Classification performance improved with increasing resolution up to a threshold, plateauing at 224 × 224 pixels. At 224 × 224 pixels, the overall classification sensitivity was 0.767 (95% CI, 0.737-0.796), and specificity was 0.862 (95% CI, 0.831-0.888).</p><p><strong>Conclusions: </strong>A resolution of 224 × 224 pixels ensures reliable human expert classification and aligns with the input requirements of many common AI-based architectures. Thus, the results of this study substantially guide projected AI development.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}